MediWound Ltd. is a biotechnology company focused on enzymatic therapeutics for non-surgical tissue repair in wound and burn care. The company develops, manufactures, and commercializes biologics that selectively remove non-viable tissue while preserving healthy tissue. Its flagship product, NexoBrid, is a topically administered biological orphan drug approved in the United States, the European Union, Japan, and Australia for the enzymatic removal of eschar in deep partial- and full-thickness thermal burns. The pipeline includes EscharEx, a bromelain-based therapy in Phase III clinical trials for chronic wounds such as venous leg ulcers and diabetic foot ulcers, and MW005, a topical therapeutic for basal cell carcinoma. MediWound operates a cGMP-certified sterile manufacturing facility and maintains in-house research and development capabilities. Commercialization is supported by a strategic partnership with Vericel Corp in the United States and direct sales or collaborations in Europe, Japan, and Australia. The company was founded in 2000.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage mediwound.com
Sector Healthcare IR page ir.mediwound.com/node/12551/pdf
Tags
enzymatic debridement, burn care, wound care, chronic wounds, diabetic foot ulcers, venous leg ulcers, basal cell carcinoma, biologics, orphan drugs, bromelain, NexoBrid, EscharEx, MW005, Vericel Corp, Coloplast, B. Braun, Convatec, Essity, Mölnlycke, Solventum, MiMedx, SANTYL
Press page —

Metrics

Valuation  
Market cap $ 177.775M
Market cap (USD) $ 177.775M
P/E -6.38
PEG —
P/BV 4.99
P/S 14.99
P/OCF -8.03
P/FCF -6.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -63.9%
ROI -50.8%
ROIC -40.3%
Profit margin -140.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 16.959M 20.222M 18.686M 26.496M 23.763M 21.763M 31.789M 3.401M 2.496M 1.558M — — —
Net profit -23.879M -30.224M -6.716M -19.599M -13.551M -9.196M 4.955M -1.057M -22.149M -18.885M -22.088M -18.875M -15.351M
Free cash flow -21.626M -19.897M -16.929M -12.44M -9.405M -7.818M 7.497M -12.676M -17.5M -17.116M -19.977M -16.859M -10.008M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 18.46 17.8 10.17 13.49 — — — — — — — — —
Price performance 12m 0.04 0.75 -0.25 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 332,000 — — — — — — — — —
↳ YoY growth +39.5%
Cash and deposits (USD) 28.9M — — — — — — — — —
Intangible assets (USD) 773,000 — — — — — — — — —
Cash flow detail
Operating cash flow (USD) -16.4M — — — — — — — — —
Purchases of property, plant and equipment (USD) -671,000 — — — — — — — — —
Purchases of intangible assets (USD) -30,000 — — — — — — — — —
Change in receivables (cash effect) (USD) 107,000 — — — — — — — — —
Change in inventories (cash effect) (USD) -873,000 — — — — — — — — —
Share-based compensation (USD) 3.17M — — — — — — — — —
Operating cash flow before change in receivables (USD) -16.6M — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -17.1M — — — — — — — — —
Income detail
Research and development expense (USD) 7.07M 5.46M 4.07M 4.97M 7.7M 10.3M 10.2M 7.47M 8.88M 14.3M
↳ 5y CAGR +28.5% +2.3% -1.5% +5.0% +7.7% +13.3% +12.9% +12.3% +13.2%
Total comprehensive income (USD) -18.9M — — — — — — — — —
Comprehensive income to owners (USD) -18.9M — — — — — — — — —
Reported Feb 21, 2017 Mar 19, 2018 Mar 25, 2019 Feb 25, 2020 Feb 25, 2021 Mar 17, 2022 Mar 16, 2023 Mar 21, 2024 Mar 19, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027

Third Quarter Revenue of $3.6 Million; 2026 Revenue Outlook Dependent on Ongoing U.S. Government Discussions

Balance Sheet Strengthened by $17.25 Million in Gross Proceeds from Underwritten Public Offering Following Quarter-End

Conference Call Today at 8:30 a.m. Eastern Time

YAVNE, Israel, November 12, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We continue to execute our strategic plan, with the EscharEx Phase III VALUE trial as our top priority. We are on track to complete the pre-specified interim sample size reassessment and full enrollment by the end of the first quarter of 2027,” said Ofer Gonen, Chief Executive Officer of MediWound. “In parallel, we are focused on bringing our expanded NexoBrid manufacturing facility into operation to meet strong global demand. We are also working diligently with the U.S. government to secure funding for our planned U.S.

CONTENTS

On November 3, 2026, MediWound Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (the “Underwriter”), relating to the issuance and sale (the “Offering”) by the Company of 1,200,000 ordinary shares, par value NIS 0.07 per share, of the Company (the “Ordinary Shares”), at a public offering price of $12.50 per Ordinary Share. The Underwriter has agreed to purchase the Ordinary Shares from the Company at a price of $12.09 per Ordinary Share, reflecting a blended underwriting discount. Under the terms of the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 180,000 Ordinary Shares on the same terms. On November 4, 2026, the Underwriter exercised in full its option to purchase 180,000 additional Ordinary Shares (the “Option Shares”).

The Offering is being made pursuant to the Company’s “shelf” registration statement on Form F-3 (File No.

October 29, 2026

PDF Version

MediWound to Report Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, November 12th at 8:30 a.m. Eastern Time

YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 12, 2026.

Following the release, Mediwound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details Toll-Free: 1-844-676-8833 Israel: 03-374-1008 International: 1-412-634-6869 Webcast: Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

Prompts

MediWound Ltd. (ticker MDWD), listed in United States.